The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
In 2026, the gut reset era is transforming weight loss by linking it inseparably to digestive health and metabolism. No longer isolated goals, bloating, slow metabolism, and weight gain are addressed holistically for lasting results. From microbiome breakthroughs to personalized tech tools, this integrated approach promises better outcomes.
Institutional investors have sidelined climate change in ESG priorities, favoring health tech fueled by Ozempic and GLP-1 drugs. A Berenberg Bank survey of 200 investors ranks health first as climate slips to fifth. Yet, climate change poses severe health threats from heatwaves to vector-borne diseases—why this mania could backfire.
Content creator Aishwarya Mohanraj's candid video about dropping from 74kg to 52kg in six months on Mounjaro has spotlighted the injectable drug. Amid PCOS and hypothyroidism challenges, her story shifts focus from Ozempic hype. But experts warn: pair it with lifestyle changes or risk weight regain.
The hype around Mounjaro's weight loss results is real, but so is 'Mounjaro face'—sharper yet tired-looking facial changes from rapid fat loss. Dermatologists and surgeons report more patients with hollowed cheeks and sagging skin seeking help. Experts reveal why it occurs and essential prevention strategies focusing on nutrition and skincare.
With GLP-1 drugs like semaglutide booming in India, dietitian Deepta Nagpall shares her exact daily meal plan to ensure adequate protein and fibre despite suppressed appetite. From omelettes to Greek yogurt, these nutrient-dense choices combat muscle loss and indigestion. Build sustainable habits for long-term success on weight loss medications.
Many patients start GLP-1 medications like Ozempic and Zepbound for obesity but quit within a year, with fewer than one in four remaining on treatment. Shockingly, 74% of those who stop plan to restart, despite experts warning against this cycling approach. This guide explores the data, risks like muscle loss, and what it means for your health.
A large German study reveals that pairing GLP-1 receptor agonists with SGLT2 inhibitors significantly lowers all-cause mortality and cardiovascular risks in type 2 diabetes patients compared to SGLT2 inhibitors alone. Common combinations like dulaglutide plus empagliflozin showed a 29% mortality reduction. Experts highlight synergy but urge caution on potential harms.
Elon Musk's dramatic before and after photos have gone viral, spotlighting his slimmer appearance after confirming Mounjaro use. The Tesla CEO's 'Ozempic Santa' post ignited speculation on GLP-1 drugs' role in his 30-pound weight loss. Understand the science behind 'Mounjaro face' and real transformations.
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
